![]() ![]() PubMed, Health Policy Reference Center, EconLit, Google Scholar, and references were searched through February 2017 for articles presenting primary data. Given personalized medicine's rising importance, this review summarizes international coverage and pricing strategies for personalized medicine and orphan drugs as well as their impact on therapy development incentives, payer budgets, and therapy access and utilization. Personalized medicine and orphan drugs share many characteristics-both target small patient populations, have uncertainties regarding efficacy and safety at payer submission, and frequently have high prices. The inclusion of the XEN® implant would generate savings of €465.24 in year 1 and €618.82 (years 2–3).Ĭonclusion: XEN® implant inclusion for surgical treatment of glaucoma would result in cost-savings for the NHS. Results: The current cost for surgical treatment of glaucoma resulted €4,665.41/patient. Unitary costs derived from a national database. The estimation of total cost (€,2016) included the following components: device costs, surgical interventions, follow-up visits, complications management, and additional procedures costs.Īn expert panel provided proportions of use and resource consumption for each intervention. ![]() The current scenario was compared along a 3-years, with a future scenario considering XEN® for mild glaucoma+cataracts cases (3%) and moderate glaucoma+cataracts and glaucoma without cataracts cases 30% (year 1), 35% (year 2) and 40% (year 3). Methods: A budget-impact analysis was designed to estimate the costs of surgical intervention in patients with not-controlled glaucoma from the perspective of the Spanish National Health System (NHS).Ī hypothetical cohort (135 patients with glaucoma) was analyzed and subdivided into 3 subgroups considering the appropriate interventions: cataracts, iStent®+cataracts, ExPRESS®±cataracts, trabeculectomy±cataracts, and non-penetrating deep sclerectomy (NPDS)±cataracts. Objective: To determine the economic impact of the XEN® Gel Stent implant inclusion into the therapeutic arsenal for surgical treatment of open-angle glaucoma in Spain.
0 Comments
Leave a Reply. |